Published in
American Society of Hematology, Blood Advances, 7(1), p. 455-466, 2017
DOI: 10.1182/bloodadvances.2016003905
Links
Tools
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients
Journal article published in 2017 by
Cirino Botta 
,
Domenico Ciliberto ,
Marco Rossi,
Nicoletta Staropoli,
Maria Cucè,
Teresa Galeano,
Pierosandro Tagliaferri,
Pierfrancesco Tassone
,
Domenico Ciliberto ,
Marco Rossi,
Nicoletta Staropoli,
Maria Cucè,
Teresa Galeano,
Pierosandro Tagliaferri,
Pierfrancesco Tassone
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points Different therapeutic agents are currently available for the treatment of RRMM. By performing an NMA, we identified a lenalidomide-dexamethasone + mAb regimen as the most active therapeutic option in this setting.